Targeting EGFR in Triple-Negative Breast Cancer
Breast tumors which are neither positive for ER, PR, or HER2 are colloquially referred to as triple-negative, due to their lack of either hormonal or growth factor related marker expression. These tumors are not responsive to either hormonal therapy or HER2-targeted agents, and thus chemotherapy is often the only effective treatment. Interestingly, expression of the HER2-related gene, HER1 — more commonly known as epidermal growth factor receptor (EGFR) — has been seen in expression profiles of triple-negative tumors, and thus EGFR-targeted therapy may be efficacious in this setting
To read full article: http://www.curetoday.com/sabcs2007/sat/brief.php |
All times are GMT -7. The time now is 08:22 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021